A novel selective inhibitor of the PP2A-STRN3 complex, STRN3-derived Hippo-activating peptide (SHAP), exerts antitumor effects by interrupting MST1/2-mediated YAP activation in gastric cancers. Here, PTPA is linked to gastric cancer.